Alphavirus vectors for vaccine production and gene therapy

Expert Review of Vaccines

Volumn 2, Issue 3, 2003, Pages 445-459

  Lundstrom, Kenneth ^a  

^a Regulon Inc   (Switzerland)

Author keywords

Alphaviruses; Immunization; Intramural injection; Liposome encapsulation; Protection against viruses and tumors; Vector development

Indexed keywords

CANCER VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS PROTEIN; VIRUS VECTOR;

ADVANCED CANCER; ALPHA VIRUS; ALPHA VIRUS VECTOR; CLINICAL RESEARCH; COMBINED IMMUNODEFICIENCY; DENDRITIC CELL; ENCAPSULATION; GENE REPLICATION; GENE TARGETING; GENE THERAPY; HOST CELL; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR REJECTION; VACCINE PRODUCTION;

EID: 0037833534     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.3.445     Document Type: Review

References (95)

1. Strauss JH, Strauss EG. The alphaviruses: gene expression, replication and evolution. Microbiol. Rev. 58, 491-562 (1994). Excellent general review on alphavirus vectors.
2. Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology 9, 1356-1361 (1991)
3. Xiong C, Levis R, Shen P et al. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243, 1189-1191 (1989).
4. Davis NL, Brown KW, Johnston RE. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology 171, 189-204 (1989).
5. Lundstrom K, Ehrengruber MU. Semliki Forest virus (SFV) vectors in neurobiology and gene therapy. Methods Mol. Med. 76, 503-523 (2003). Contains instructions for using SFV vectors.
6. Berglund P, Sjöberg M, Garoff H et al. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology 11, 916-920 (1993).
7. Dubuisson J, Rice CM. Sindbis virus attachment: isolation and characterization of mutants with impaired binding to vertebrate cells. J. Virol. 67, 3363-3374 (1993).
8. Pushko P, Parker M, Ludwig GV et al. Replicon-helper systems from Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo. Virology 239, 389-401 (1997).
9. Smerdou C, Liljeström P. Two-helper RNA system for production of recombinant Semliki Forest virus particles. J. Virol 73, 1092-1098 (1999).
10. Frolov I, Frolova E, Schlesinger S. Sindbis virus replicons and Sindbis virus: assembly of chimeras and of particles deficient in virus RNA. J. Virol. 71, 2819-2829 (1997).
11. Polo JM, Belli BA, Driver DA et al. Stable alphavirus packaging cell lines for Sindbis virus- and Semliki Forest virus-derived vectors. Proc. Natl Acad Sci. USA 96, 4598-4603 (1999). First description of alphavirus packaging cell lines.
12. Hariharan MJ, Driver DA, Townsend K et al. DNA immunization against herpes simplex virus: enhanced efficacy using Sindbis-based vector. J Virol. 72, 950-958 (1998).
13. Berglund P, Smerdou C, Fleeton MN et al. Enhancing immune response using suicidal vaccines. Nat. Biotechnol. 16, 562-565 (1998).
14. Lundstrom K, Schweitzer C, Rotmann D et al. Semliki Forest virus vectors: efficient vehicles for in vitro and in vivo gene delivery. FEBS Lett. 504, 99-103 (2001).
15. Lundstrom K. Semliki Forest virus vectors for rapid and high-level expression of integral membrane proteins. Biochim. Biophys. Acta 1610, 90-96 (2003).
16. Ehrengruber MU, Lundstrom K, Schweitzer C et al. Recombinant Semliki Forest virus and Sindbis virus efficiently infect neurons in hippocampal slice cultures. Proc. Natl Acad. Sci. USA 96, 7041-7046 (1999).
17. Maletic-Savatic M, Malinow R, Svoboda K. Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity. Science 283, 1923-1927 (1999).
18. Lundstrom K, Richards JG, Pink JR et al. Efficient in vivo expression of a reporter gene in rat brain after injection of replication-deficient Semliki Forest virus. Gene Ther. Mol. Biol. 3, 15-23 (1999).
19. Altman-Hamandzic S, Grocedose C, Ma J-X et al. Expression of β-galactosidase in mouse brain. Utilization of a nonreplicative Sindbis virus vector as a neuronal gene delivery system. Gene Ther. 4, 815-822 (1997).
20. Davis NI, West A, Reap E et al. Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53, 209-211 (2002).
21. Brinster C, Chen M, Boucreux D et al. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles. J. Gen. Virol. 83, 369-381 (2002).
22. Chen M, Hu KF, Rozell B et al. Vaccination with recombinant alphavirus or immunestimulating complex antigen against respiratory syncytial virus. J. Immunol. 169, 3208-3216 (2002).
23. Harrington PR, Yount B, Johnston RE et al. Systemic, mucosal and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J. Virol. 76, 730-742 (2002).
24. Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T-lymphocytes specific for the viral nucleoprotein. J. Virol. 75, 2660-2664 (2001).
25. Pushko P, Bray M, Ludwig GV et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea-pigs and mice from Ebola hemorrhagic fever virus. Vaccine 19, 142-153 (2000). Demonstration of immunization with alphavirus resulting in protection against viral challenge.
26. Giesbert TW, Pushko P, Anderson K et al. Evaluation in nonhuman primates of vaccines against Ebola virus. Emerg. Infect. Dis. 8, 503-507 (2002).
27. Andersson C, Vasconcelos NM, Sievertzon MA et al. Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparum antigen Pf332. Scand. J. Immunol. 54, 117-124 (2001).
28. Krasemann S, Jürgens T, Bodemer W. Generation of monoclonal antibodies against prion proteins with an unconventional nudeic acid-based immunization strategy. J. Biotechnol. 73, 119-129 (1999).
29. Kirman JR, Turon T, Su H et al. Enhanced immunogenicity to Mycobacterium tuberculosis by vaccination with an alphavirus plasmid replicon expressing antigen 85A. Infect. Immun. 71, 575-579 (2003).
30. Lee JS, Dyas BK, Nystrom SS et al. Immune protection against staphylococcal enterotoxin-induced toxic shock by vaccination with a Venezuelan equine encephalitis virus replicon. J. Infect. Dis. 185, 1192-1196 (2002).
31. Bennett AM, Elvin SJ, Wright AJ et al. An immunological profile of BALB/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan encephalitis virus vaccine. Vaccine 19, 337-347 (2000).
32. Hart MK, Casell-Stephan K, Bakken R et al. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 18, 3067-3075 (2000).
33. Edelman R, Tacket CO, Wassermann SS et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62, 681-685 (2000).
34. Schoepp RJ, Smith JF, Parker MD. Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates. Virology 305, 299-309 (2002).
35. Ying H, Zaks TZ, Wang R-F et al. Cancer therapy using self-replicating RNA vaccine. Nature Med. 5, 823-827 (1999). Descrption of the use of replicon RNA for prophylactic and therapeutic effect.
36. Colmenero P, Liljeström P, Jondal M. Induction of P185 tumor immunity by recombinant Semliki Forest virus expressing P1A gene. Gene Ther. 6, 1728-1733 (1999). Immunity established against tumor after the administration of SFV expressing tumor antigen.
37. Velders MP, McElhiney S. Cassetti MC et al. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res. 61, 7861-7867 (2001).
38. Daemen T, Regts J, Holtrop M et al. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7. Gene Ther. 9, 85-94 (2002).
39. Yamanaka R, Zullo SA, Tanaka R et al. Enhancement of antitumor response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki Forest virus-mediated complementary DNA. J. Neurosurg. 94, 478-481 (2001).
40. Leitner W, Hwang LN, DeVeer MJ et al. Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nat. Med. 9, 33-39 (2003).
41. Cheng WF, Hung CF, Hsu KF et al. Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion. Hum Gene Ther. 13, 553-568 (2002). Enhanced delivery of tumor antigen by fusion to VP22.
42. Yamanaka R, Zullo SA, Ramsey J et al. Marked enhancement of antitumor responses in mouse brain tumor models by geentically modified dendritic cells producine Semliki Forest virus-mediated interleukin-12. J. Neurosurg. 97, 611-618 (2002).
43. Ohno K, Sawai K, Ijima Y et al. Cellspecific targeting of Sindbis virus vectors displaying IgG binding domains of protein A. Nat. Biotechnol. 15, 763-767 (1997). First description of SIN targeting by introduction of protein A domains in envelope structure.
44. Cheng WF, Hung CF, Hsu KF et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by targeting antigen to endosomal/lysosomal compartments. Hum. Gene Ther. 12, 235-252 (2001).
45. Gardner JP, Frolov I, Perri S et al. Infection of human dendritic cells by a sindbis virus replicon vector is determined by a single amino acid substitution in the E2 glycoprotein. J. Virol. 74, 11849-11857 (2000). Targeted expression in dendritic cells by single point mutation in SIN E2 gene.
46. MacDonald GH, Johnston RE. Role of dendritic cell targeting in Venezuelan equine encephalitis virus pathogenesis. J. Virol. 74, 914-922 (2000).
47. Hardy PA, Mazzini MJ, Schweitzer C et al. Recombinant Semliki Forest virus infects and kills human prostate cell lines and prostatic duct epithelial cells ex vivo. Int. J. Med. Mol. 5, 241-245 (2000).
48. Asselin-Paturel C, Lassau N, Guinebretiere J-M et al. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Ther. 6, 606-615 (1999). Tumor regression observed after intratumoral injection of SFV expressing IL-12.
49. Murphy A-M, Morris-Downes MM, Sheahan BJ et al. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles. Gene Ther. 7, 1477-1482 (2000).
50. Murphy AM, Sheahan BJ, Atkins G. Induction of apoptosis in Bcl-2-expressing rat prostate cancer cells using the Semliki Forest virus vector. Int. J. Cancer 94, 572-578 (2001).
51. Scallan MF, Allsopp TE, Fazakerley JK. Bcl-2 acts early to restrict Semliki Forest virus replication and delays virus-induced programmed cell death. J. Virol. 71, 1583-1590 (1997).
52. Lundstrom K, Boulikas T. Breakthrough in cancer therapy: encapsulation of drugs and viruses. Curr. Drug Disc. Nov., 19-23 (2002). Targeted expression to tumors after encapsulation of SFV particles allowing Phase I clinical trials on kidney carcinoma and melanoma.
53. Mathiot CC, Grimaud G, Garry P. An outbreak of human Semliki Forest virus infections in Central African Republic. Am. J. Trop. Med. Hyg. 42, 386-393 (1990).
54. Weaver SC, Salas R, Rico-Hesse R. Reemergence of epidemic Venezuelan equine encephalomyelitis in South America. VEE Study Group. Lancet 348, 436-440 (1996).
55. Dryga SA, Dryga OA, Schlesinger S. Identification of mutants in a Sindbis virus variant able to establish persistent infection in BHK cells: the importance of a mutation in the nsP2 gene. Virol. 228, 74-83 (1997).
56. Agapov EV, Frolov I, Lindenbach BD et al. Non-cytopathogenic Sindbis RNA vectors for heterologous gene expression. Proc. Natl Acad. Sci. USA 95, 12989-12994 (1998).
57. Boorsma M, Nieba L, Koller D et al. A temperature-regulated replicon-based DNA expression system. Nat. Biotechnol. 18, 429-432 (2000). Cold inducible SIN vector with reduced cytotoxicity.
58. Perri S, Driver DA, Gardner JP et al. Replicon vectors derived from Sindbis virus and Semliki Forest virus that established persistent replication in host cells. J. Virol. 74, 9802-9807 (2000).
59. Lundstrom K, Abenavoli A, Malgaroli A et al. Novel Semliki Forest virus vectors with reduced cytotoxicity and temperature sensitivity for long-term enhancement of transgene expression. Mol. Ther. 7, 202-209 (2003).
60. Lundstrom K, Rotmann D, Hermann D et al. Novel mutant Semliki Forest virus vectors: gene expression and localization studies in neuronal cells. Histochem Cell Biol. 115, 83-91 (2001).
61. Ehrengruber MU, Renggli M, Raineteau O et al. Semliki Forest virus A7(74) transduces hippocampal neurons and glial cells in a temperature-dependent dual manner. J. Neurovirol. 9, 16-28 (2003).
62. Reddy JR, Kwang J, Varthakavi V et al. Semliki Forest virus vector carrying the bovine viral diarrhea virus NS3 (p80) cDNA induced immune responses in mice and expressed BVDV protein in mammalian cells. Comp. Immunol. Microbiol. Infect. Dis. 22, 231-246 (1999).
63. Balasuriya UB, Heidner HW, Hedges JF et al. Expression of the two major envelope proteins of equine arteritis virus as a heterodimer is necessary for induction of neutralizing antibodies in mice immunized with recombinant Venezuelan equine encephalitis virus replicon particles. J. Virol. 74, 10623-10630 (2000).
64. Wilson JA, Bray M, Bakken R et al. Vaccine potential of Ebola virus VP24, VP30, VP35 and VP40 proteins. Virology 286, 384-390 (2001).
65. Driver DA, Latham EM, Polo JM et al. Layered amplification of gene expression with a DNA delivery system. Ann. NY Acad Sci. 772, 261-264 (1995).
66. Vidalin O, Fuornillier A, Renard N et al. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki Forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens. Virology 276, 259-270 (2000).
67. Brand D, Lemiale F, Turbica I et al. Comparative analysis of humoral immune responses to HIV Type I envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus partcles. AIDS Res. Hum. Retroviruses 14, 1369-1377 (1998).
68. Giraud A, Ataman-Onal Y, Battail N et al. Generation of monoclonal antibodies to naive human immunodeficiency virus Type I envelope glycoprotein by immunization of mice with naked RNA. J. Virol. Methods 79, 75-84 (1999).
69. Caley IJ, Betts MR, Irlbeck DM et al. Humoral, mucosal and cellular immunity in response to a human immunodeficiency virus Type I immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71, 3031-3038 (1997).
70. Hsu KF, Hung CF, Cheng WF et al. Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen. Gene Ther. 8, 376-383 (2001).
71. Cheng WF, Hung CH, Chai CY et al. Enhancement of sindbis virus self-replicating RNA vaccine potency by linkage of herpes simplex virus Type 1 VP22 protein to antigen. J. Virol. 75, 2368-2376 (2001).
72. Cheng WF, Hung CH, Chai CY et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen. J. Immunol. 166, 6218-6226 (2001).
73. Schlesinger S, Dubensky TW. Alphavirus vectors for gene expression and vaccines. Curr. Opin. Biotechnol. 10, 434-439 (1999).
74. Phenix KV, Wark K, Luke CJ et al. Recombinant Semliki Forest virus vector exhibits potential for avian virus vaccine development. Vaccine 19, 3116-3123 (2001).
75. Malone JG, Berglund P, Liljeström P et al. Mucosal immune responses associated with polynucleotide vaccination. Behring Inst. Mitt. 98, 63-72 (1997).
76. Berglund P, Smerdou C, Fleeton MN et al. Enhancing immune response using suicidal vaccines. Nat. Biotechnol. 16, 562-565 (1998).
77. Scultz-Cherry S, Dybing JK, Davis NL et al. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects chicken against lethal infection with Hong Kong-origin H5N1 viruses. Virology 278, 55-59 (2000).
78. Zhou X, Berglund P, Rhodes G et al. Self-replicating Semliki Forest virus RNA as a recombinant vaccine. Vaccine 12, 1510-1513 (1994).
79. Vignuzzi M, Gerbaud S, van der Werf S et al. Naked RNA immunization with replicons from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T-cell response against the influenza A virus nucleoprotein. J. Gen. Virol. 82, 1737-1747 (2001).
80. Pugachev KV, Mason PW, Shope RE et al. Double-subgenomic Sindbis virus recombinants expressing immunogenic proteins of Japanese encephalitis virus induce significant protection in mice against lethal JEV injection. Virology 212, 587-594 (1995).
81. Fleeton MN, Liljeström P, Sheahan BJ et al. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J. Gen. Virol. 81, 749-758 (2000).
82. Morris-Downes MM, Phenix KV, Smith J et al. Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 19, 1978-1988 (2001).
83. Hevey M, Negley D, VanderZanden L et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine 20, 586-593 (2001).
84. Hevey M, Negley D, Pushko P et al. Marburg virus vaccines based upon alphavirus replicons protect guinea-pigs and nonhuman primates. Virology 251, 28-37 (1998).
85. Colombage G, Hall R, Pavy M et al. DNA-based and alphavirus-vectored immunization with prM and E proteins elicit long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250, 151-163 (1998).
86. Fleeton MN, Chen M, Berglund P et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus and a tickborne encephalitis virus. J. Infect. Dis. 183, 1395-1398 (2001).
87. Kamrud KI, Hooper JW, Elgh F et al. Comparison of the protective efficacy of naked DNA, DNA-based Sindbis replicon and packaged Sindbis replicon vectors expressing Hantavirus structural genes in hamsters. Virology 263, 209-219 (1999).
88. Berglund P, Quassada-Rolander M, Putkonen P et al. Outcome of immunization of cymolgus monkeys with recombinant Semliki Forest virus encoding human immunodeficiency virus Type 1 envelope protein and challenge with a high dose of SHIV-4 virus. AIDS Res. Hum. Retroviruses 13, 1487-1595 (1997).
89. Mossman SP, Bex F, Berglund P et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj 14 disease by a recombinant Semliki Forest virus gp160 vaccine and by gp120 subunit vaccine. J. Virol. 70, 1953-1960 (1996).
90. Davis NL, Caley IJ, Brown KW et al. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. J. Virol. 74, 371-378 (2000).
91. Nilsson C, Makitalo B, Berglund P et al. Enhanced simian immunodeficiency virus-specific immune response in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19, 3526-3536 (2001).
92. Tsuji M, Bergmann C, Takita-Sonoda Y et al. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J. Virol. 72, 6907-6910 (1998).
93. Elvin SJ, Bennett AM, Phillpotts RJ. Role for mucosal immune responses and cell-mediated immune functions in protection from airborne challenge with Venezuelan equine encephalitis virus. J. Med. Virol. 67, 384-393 (2002).
94. Colmenero P, Chen M, Castanos-Velez E et al. Immunotherapy with recombinant SFV-replicons expressing the P815 tumor antigen or IL-12 induces tumor regression. Int. J. Cancer 98, 554-560 (2002).
95. Ying H, Zeng G, Black KL. Innovative cancer vaccine strategies based on the identification of tumor-associated antigens. BioDrugs 15, 819-831 (2001).